Density of tryptase-positive mast cells correlated with the presence of <i>H. pylori</i> in gastric neoplasia

Micu, Gianina; Stăniceanu, Florica; Sticlaru, Liana; Popp, Cristiana; Bastian, Alexandra; Grămadă, Eliza; Rimbaș, Mihai; Mateescu, Bogdan

doi:10.1515/rjim-2015-0030

Cited by 1 publication

(2 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…burden of this malignancy [82,83]. With its widespread prevalence, infecting over 50% of the world s population, the significance of this bacterium in GC development cannot be underestimated [84].…”

Section: Dna Damage Induces Gastric Carcinogenesismentioning

confidence: 99%

“…It exhibits remarkable adaptability, colonizing the human stomach [81]. Classified as a class I pathogenic agent for GC by the World Health Organization, H. pylori infection holds a prominent position in the global burden of this malignancy [82,83]. With its widespread prevalence, infecting over 50% of the world's population, the significance of this bacterium in GC development cannot be underestimated [84].…”

Section: Dna Damage Induces Gastric Carcinogenesismentioning

confidence: 99%

See 1 more Smart Citation

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

Chen,

Hu,

Zhuang

et al. 2023

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) is a common and aggressive cancer of the digestive system, exhibiting high aggressiveness and significant heterogeneity. Despite advancements in improving survival rates over the past few decades, GC continues to carry a worrisome prognosis and notable mortality. As a result, there is an urgent need for novel therapeutic approaches to address GC. Recent targeted sequencing studies have revealed frequent mutations in DNA damage repair (DDR) pathway genes in many GC patients. These mutations lead to an increased reliance on poly (adenosine diphosphate-ribose) polymerase (PARP) for DNA repair, making PARP inhibitors (PARPi) a promising treatment option for GC. This article presents a comprehensive overview of the rationale and development of PARPi, highlighting its progress and challenges in both preclinical and clinical research for treating GC.

show abstract

Section: Dna Damage Induces Gastric Carcinogenesismentioning

confidence: 99%